Ananda Developments - Ananda joins cannabinoid R&D Group
Announcement provided by
Ananda Developments Plc · ANA31/05/2024 07:00
![](https://tracker.live.rns-distribution.com/track.live-rns/5204639_d9353a075fe0b610698e373da828b7e4.png)
31 May 2024
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda Developments joins new taskforce set to establish the
Ananda developments plc (AQSE: ANA), a company focused on becoming a leading provider of regulator approved CBD-based medicines for chronic inflammatory pain conditions is pleased to announce that it is a founding member of the Cannabinoid Research and Development Group, established and co-Chaired by George Freeman MP and Professor Trevor Jones.
The group will develop and execute a strategy to establish the
The
At present, only three cannabis-based medicines have been approved for prescription in the
The group will be consulting on its plans in the coming months with a view to producing its first strategy paper to the new government in July.
Ananda CEO, Melissa Sturgess, commented: "Ananda Developments is pleased to be part of this taskforce and contribute to creating a robust framework for scientific exploration and drug development which benefits the
Read the announcement in full here:
For more information please contact:
InvestorHub Engage with us directly at Ananda Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Executive Director Jeremy Sturgess-Smith
|
+44 (0)7463 686 497 ir@anandadevelopments.com |
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe
|
+44 (0)20 3470 0470 |
Corporate Broking Abigail Wayne Rob Rees
|
|
Yellow Jersey PR Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based
medicines for the treatment of complex, chronic inflammatory pain conditions.
For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/peggNe
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.